September 15, 2025 — Leads & Copy —
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) presented data from its ATH434-201 Phase 2 clinical trial in Multiple System Atrophy (MSA) at the American Neurological Association (ANA) Annual Meeting in Baltimore, MD.
The poster, “ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy,” was presented by Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center. The study showed clinically meaningful efficacy in modifying disease progression at both 50 and 75 mg doses, with target engagement reducing iron accumulation in affected brain regions. The drug was well tolerated with similar adverse event rates as placebo.
CEO of Alterity, David Stamler, M.D., said the data demonstrates meaningful clinical impact, including reduced disease severity, improvements in core symptoms, and maintained function. These results reinforce ATH434’s potential as a disease modifying therapy.
ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and Orphan Drug Designation by the FDA and the European Commission for the treatment of MSA.
Remy Bernarda, Investor Relations Advisory Solutions, ir@alteritytx.com, +1 (415) 203-6386
Casey McDonald, Tiberend Strategic Advisors, Inc., cmcdonald@tiberend.com, +1 (646) 577-8520
Source: Alterity Therapeutics
